Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase (BTK) degrader bexobrutideg (NX‑5948) in blood